vs
EXACT SCIENCES CORP（EXAS）与FirstCash Holdings, Inc.（FCFS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是FirstCash Holdings, Inc.的1.8倍（$878.4M vs $501.3M），FirstCash Holdings, Inc.净利率更高（20.8% vs -9.8%，领先30.6%），EXACT SCIENCES CORP同比增速更快（23.1% vs 21.2%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 16.9%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
FirstCash Holdings, Inc.是总部位于美国得克萨斯州沃斯堡的典当企业，在美国及拉丁美洲多地运营线下典当零售门店，为纳斯达克证券交易所公开上市企业，在美洲典当服务领域拥有成熟的业务布局与完善的运营网络。
EXAS vs FCFS — 直观对比
营收规模更大
EXAS
是对方的1.8倍
$501.3M
营收增速更快
EXAS
高出1.9%
21.2%
净利率更高
FCFS
高出30.6%
-9.8%
两年增速更快
EXAS
近两年复合增速
16.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $501.3M |
| 净利润 | $-86.0M | $104.2M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 28.5% |
| 净利率 | -9.8% | 20.8% |
| 营收同比 | 23.1% | 21.2% |
| 净利润同比 | 90.1% | 24.7% |
| 每股收益（稀释后） | $-0.45 | $2.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFCFS
| Q4 25 | $878.4M | $501.3M | ||
| Q3 25 | $850.7M | $411.0M | ||
| Q2 25 | $811.1M | $385.1M | ||
| Q1 25 | $706.8M | $371.1M | ||
| Q4 24 | $713.4M | $413.7M | ||
| Q3 24 | $708.7M | $363.1M | ||
| Q2 24 | $699.3M | $363.5M | ||
| Q1 24 | $637.5M | $366.8M |
净利润EXASFCFS
| Q4 25 | $-86.0M | $104.2M | ||
| Q3 25 | $-19.6M | $82.8M | ||
| Q2 25 | $-1.2M | $59.8M | ||
| Q1 25 | $-101.2M | $83.6M | ||
| Q4 24 | $-864.6M | $83.5M | ||
| Q3 24 | $-38.2M | $64.8M | ||
| Q2 24 | $-15.8M | $49.1M | ||
| Q1 24 | $-110.2M | $61.4M |
毛利率EXASFCFS
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASFCFS
| Q4 25 | -9.4% | 28.5% | ||
| Q3 25 | -3.0% | 27.4% | ||
| Q2 25 | -0.3% | 21.1% | ||
| Q1 25 | -13.6% | 30.0% | ||
| Q4 24 | -122.8% | 26.5% | ||
| Q3 24 | -5.6% | 23.5% | ||
| Q2 24 | -3.8% | 18.2% | ||
| Q1 24 | -16.7% | 22.3% |
净利率EXASFCFS
| Q4 25 | -9.8% | 20.8% | ||
| Q3 25 | -2.3% | 20.1% | ||
| Q2 25 | -0.1% | 15.5% | ||
| Q1 25 | -14.3% | 22.5% | ||
| Q4 24 | -121.2% | 20.2% | ||
| Q3 24 | -5.4% | 17.9% | ||
| Q2 24 | -2.3% | 13.5% | ||
| Q1 24 | -17.3% | 16.7% |
每股收益（稀释后）EXASFCFS
| Q4 25 | $-0.45 | $2.35 | ||
| Q3 25 | $-0.10 | $1.86 | ||
| Q2 25 | $-0.01 | $1.34 | ||
| Q1 25 | $-0.54 | $1.87 | ||
| Q4 24 | $-4.69 | $1.86 | ||
| Q3 24 | $-0.21 | $1.44 | ||
| Q2 24 | $-0.09 | $1.08 | ||
| Q1 24 | $-0.60 | $1.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $125.2M |
| 总债务越低越好 | — | $2.2B |
| 股东权益账面价值 | $2.4B | $2.3B |
| 总资产 | $5.9B | $5.3B |
| 负债/权益比越低杠杆越低 | — | 0.98× |
8季度趋势，按日历期对齐
现金及短期投资EXASFCFS
| Q4 25 | $964.7M | $125.2M | ||
| Q3 25 | $1.0B | $130.2M | ||
| Q2 25 | $858.4M | $101.5M | ||
| Q1 25 | $786.2M | $146.0M | ||
| Q4 24 | $1.0B | $175.1M | ||
| Q3 24 | $1.0B | $106.3M | ||
| Q2 24 | $946.8M | $113.7M | ||
| Q1 24 | $652.1M | $135.1M |
总债务EXASFCFS
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.5B |
股东权益EXASFCFS
| Q4 25 | $2.4B | $2.3B | ||
| Q3 25 | $2.5B | $2.2B | ||
| Q2 25 | $2.5B | $2.1B | ||
| Q1 25 | $2.4B | $2.1B | ||
| Q4 24 | $2.4B | $2.1B | ||
| Q3 24 | $3.2B | $2.0B | ||
| Q2 24 | $3.2B | $2.0B | ||
| Q1 24 | $3.1B | $2.0B |
总资产EXASFCFS
| Q4 25 | $5.9B | $5.3B | ||
| Q3 25 | $5.9B | $5.2B | ||
| Q2 25 | $5.8B | $4.5B | ||
| Q1 25 | $5.7B | $4.4B | ||
| Q4 24 | $5.9B | $4.5B | ||
| Q3 24 | $6.7B | $4.4B | ||
| Q2 24 | $6.7B | $4.3B | ||
| Q1 24 | $6.4B | $4.2B |
负债/权益比EXASFCFS
| Q4 25 | — | 0.98× | ||
| Q3 25 | — | 1.01× | ||
| Q2 25 | — | 0.79× | ||
| Q1 25 | — | 0.83× | ||
| Q4 24 | — | 0.85× | ||
| Q3 24 | — | 0.87× | ||
| Q2 24 | — | 0.85× | ||
| Q1 24 | — | 0.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $206.6M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 1.98× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASFCFS
| Q4 25 | $151.7M | $206.6M | ||
| Q3 25 | $219.9M | $135.8M | ||
| Q2 25 | $89.0M | $116.9M | ||
| Q1 25 | $30.8M | $126.6M | ||
| Q4 24 | $47.1M | $198.1M | ||
| Q3 24 | $138.7M | $113.1M | ||
| Q2 24 | $107.1M | $106.2M | ||
| Q1 24 | $-82.3M | $122.5M |
自由现金流EXASFCFS
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASFCFS
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASFCFS
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASFCFS
| Q4 25 | — | 1.98× | ||
| Q3 25 | — | 1.64× | ||
| Q2 25 | — | 1.95× | ||
| Q1 25 | — | 1.51× | ||
| Q4 24 | — | 2.37× | ||
| Q3 24 | — | 1.74× | ||
| Q2 24 | — | 2.16× | ||
| Q1 24 | — | 2.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FCFS
| US Pawn Segment | $292.2M | 58% |
| Retail POS Payment Solutions | $209.8M | 42% |
